IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
Rhea-AI Summary
IntraGel Therapeutics announced a strategic collaboration with UroGen Pharma (Nasdaq: URGN), combining an equity investment of up to $7 million with an Option and Research License Agreement. The investment is intended to support IntraGel’s Phase 2 clinical study of TumoCure, an investigational SRGel‑based cisplatin therapy for advanced head and neck cancer.
Under the Option Agreement, UroGen receives an exclusive option to obtain an exclusive, worldwide license to develop and commercialize TumoCure after completion of Phase 2. UroGen also gains research access to IntraGel’s SRGel biodegradable sustained‑release platform and options for exclusive worldwide licenses to develop and commercialize up to three additional oncology products using SRGel with compounds designated by UroGen.
Positive
- UroGen commits up to $7 million equity investment in IntraGel
- Exclusive option for UroGen to license TumoCure worldwide post‑Phase 2
- Research access to SRGel platform with options on up to three more oncology products
- Phase 1b TumoCure data showed general safety and tolerability with low systemic cisplatin exposure
Negative
- None.
News Explained
IntraGel and UroGen have signed the collaboration and investment agreements, but the release describes UroGen’s equity investment as up to
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 17 | NDA submission | Positive | +1.9% | Submitted NDA for UGN-103, supported by Phase 3 UTOPIA data in 99 patients. |
| Aug 05 | Q2 earnings report | Positive | +16.3% | Reported higher revenue, narrower net loss, and ZUSDURI sales growth in Q2 2026. |
| Jul 29 | Earnings-date notice | Neutral | -1.1% | Scheduled Q2 2026 results and investor webcast before August 5 market open. |
| Jul 15 | Patent allowance | Positive | +1.6% | Received patent allowance expected to protect ZUSDURI and UGN-103 into July 2044. |
| Jul 08 | FDA IND clearance | Positive | +0.7% | Received FDA IND clearance enabling planned Phase 1 enrollment in Q4 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive news events aligned with positive 24-hour reactions in four cases; the earnings-date notice diverged with a -1.05% move.
Key Terms
sustained-release formulation technical
cisplatin medical
monoclonal antibody medical
glp-1 analogues medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- IntraGel secures up to
$7 million - UroGen gains access to IntraGel's biodegradable sustained-release gel platform with broad potential across solid tumors, as well as an exclusive option to acquire worldwide rights to TumoCure
NAZARETH,
In a related equity investment agreement, UroGen will invest up to
"UroGen's leadership in localized oncology therapies and commercial-stage experience make them an ideal collaborator to help advance the SRGel platform and accelerate the development of TumoCure," said Peter Siman, Ph.D., Chief Executive Officer and Co-Founder, IntraGel Therapeutics. "We see this collaboration as an important validation of our SRGel platform and the clinical potential of our lead investigational product, TumoCure, while creating a strong pathway to accelerate development across multiple oncology indications."
"This agreement represent an important step in expanding UroGen's oncology pipeline and our technological capabilities," said Liz Barrett, President and Chief Executive Officer of UroGen Pharma. "IntraGel's biodegradable, sustained-release technology complements our expertise in local drug delivery while creating significant optionality for future innovation. Beyond the opportunity to advance TumoCure, we believe the SRGel platform could potentially enable multiple therapeutic approaches across a range of solid tumors and provide a foundation for new product opportunities over time."
Dr. Siman added, "In parallel, we are continuing to advance additional therapeutic candidates in our pipeline based on the broadly applicable SRGel platform including our internally developed IG-003 with GLP-1 analogues for weight management, and monoclonal antibody and peptide programs developed through ongoing collaborations."
SRGel is a biodegradable depot technology designed to enable sustained release of therapeutic agents over extended periods. The platform's flexibility supports multiple therapeutic modalities and indications. In oncology, SRGel has potential applicability across a broad range of solid tumor settings, including bladder, skin, brain, gastrointestinal and testicular cancers, creating opportunities for future localized oncology treatments beyond the initial collaboration programs.
TumoCure is an investigational cisplatin product formulated with IntraGel's proprietary SRGel platform, designed to enable prolonged localized drug exposure while limiting systemic exposure. Presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Phase 1b clinical data demonstrated that TumoCure was generally safe and well tolerated, showed low systemic cisplatin exposure, and provided early indications of anti-tumor activity in a heavily pretreated patient population, including patients with cisplatin treatment-resistant disease1. Investigators also reported improvements in tumor-related symptoms in certain patients. These findings support continued clinical development of TumoCure and further expansion of the SRGel platform as a potential approach for sustained local therapy across additional solid tumors while minimizing systemic exposure.
About SRGel
SRGel is IntraGel's proprietary injectable hydrophobic gel-like drug delivery platform designed to enable sustained, tailored drug release. Built on a proprietary water-free and solvent-free fatty-acids based polymer matrix, SRGel is engineered to provide controlled, and prolonged release of therapeutics agents following a single administration, with applicability for both localized delivery at the target site and sustained systemic exposure. The technology is designed, when injected intratumorally, to maintain high local drug concentrations while minimizing systemic exposure and associated toxicities. SRGel is compatible with a broad range of therapeutic modalities, including small molecules, peptides and biologics, and may be applicable across therapeutic areas and indications, including weight loss management and inflammatory diseases.
About TumoCure
TumoCure is IntraGel's lead product candidate and the first clinical application of the SRGel platform. TumoCure consists of cisplatin incorporated into the SRGel biodegradable matrix and is administered as a single intratumoral injection. The investigational therapy is designed to provide sustained delivery of cisplatin directly within tumor tissue over several months while limiting systemic exposure. TumoCure is Phase 2-ready and is being developed for patients with locally advanced, inoperable head and neck cancers, who are ineligible for systemic cisplatin-based chemoradiation. IntraGel is pursuing development through the
About IntraGel Therapeutics
IntraGel develops long-acting injectable therapies that can replace daily or weekly dosing with a single administration, or convert large, painful injections into small-volume, highly concentrated doses. SRGel is IntraGel's long-acting injectable platform designed to support safer, more durable treatment options across multiple therapeutic areas and modalities, including small molecules, peptides, and biologics. IntraGel's lead product candidate based on the SRGel platform, TumoCure, for the treatment of head and neck cancer is Phase 2-ready. In addition, SRGel was shown in both in vivo and in vitro studies to deliver stable, long-acting exposure with GLP-1 analogues, monoclonal antibodies and peptides. IntraGel's technology is based on the research of Prof. Avi Domb, the School of Pharmacy, Institute for Drug Research at the Hebrew University of Jerusalem and IntraGel's Scientific Founder and Chief Scientist. The Company was established as part of NGT, a unique VC and technology incubator dedicated to investing in visionary entrepreneurs from promising early-stage healthcare startups that bring positive social impact.
Media Contact:
Tsipi Haitovsky
Global Media Liaison
Tsipihai5@gmail.com
1 J.B. Vermorken, et. al European Journal of Cancer and Clinical Oncology, 1982. 18(11): p. 1069-1074.
View original content:SOURCE IntraGel Therapeutics